Population-based impact of pneumococcal conjugate vaccine in young children

Pediatrics
Katherine A PoehlingMarie R Griffin

Abstract

To determine the population impact of pneumococcal conjugate vaccine (PCV) on pneumococcal-related diseases, including pneumonia and otitis media. Using administrative data from Tennessee Medicaid and 3 commercial insurance plans in upstate New York, we measured annual rates of medical visits for pneumococcal-related diseases (pneumococcal and nonspecific pneumonia and invasive disease; otitis media) and pneumococcal-unrelated diseases (other acute respiratory illnesses). Disease rates before (1995-2000 in Tennessee; 1998-2000 in New York) and after (2000-2002) PCV licensure were calculated for children aged <2 years (eligible for PCV) and those 3 to 5 years (not routinely given PCV). Because annual variations should affect both age groups similarly and vaccine-related outcomes should preferentially decline in younger children, ratios (<2:3-5 years) of disease rates before and after PCV licensure were compared. Expected disease rates were calculated for children aged <2 years in each postvaccine year. The difference between observed and expected disease rates was the estimated vaccine effect. In 2001-2002, there were 67 380 and 9485 child-years of observation for Tennessee and New York children aged <2 years, respectively. We o...Continue Reading

Citations

May 6, 2009·Archives of Pediatrics & Adolescent Medicine·Jennifer M StancilKatherine A Poehling
May 31, 2008·Current Infectious Disease Reports·Eugene Leibovitz
May 31, 2008·Current Infectious Disease Reports·Catherine A Lexau
Jul 12, 2013·The New England Journal of Medicine·Marie R GriffinCarlos G Grijalva
Jun 7, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sarah S Long
Mar 9, 2005·The Nurse Practitioner·Linda H Carlson
Apr 9, 2005·Current Opinion in Pulmonary Medicine·Constantine A Sinaniotis, Athanassios C Sinaniotis
May 29, 2007·The Pediatric Infectious Disease Journal·Gordean BjornsonGregory J Tyrrell
Dec 12, 2007·The Pediatric Infectious Disease Journal·Michael E Pichichero, Janet R Casey
Oct 30, 2012·The Pediatric Infectious Disease Journal·Kristina A BryantDaniel A Scott
Jan 1, 2010·Pediatric Emergency Care·Sarah Christian-KoppFred W McDonald
Nov 23, 2006·Archives of Disease in Childhood·S L Block
Dec 5, 2012·International Journal of Otolaryngology·Sylvia TaylorMark Haggard
Mar 3, 2010·Pediatrics in Review·Jane M Gould, Paul S Matz
Dec 7, 2007·Paediatric Drugs·Krishne Chetty, Anne H Thomson
Mar 17, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sylvia TaylorMark Haggard
Jan 30, 2010·Expert Review of Anti-infective Therapy·Eugene LeibovitzNitza Newman
Dec 18, 2010·Expert Review of Vaccines·E David G McIntosh, Ralf R Reinert
Feb 7, 2008·Expert Review of Vaccines·Carlos G Grijalva, Marie R Griffin
Dec 24, 2004·Pediatric Annals·Margaret A Kenna
Mar 14, 2009·Vaccine·Eugene Leibovitz
Jan 15, 2008·Annals of Epidemiology·Maryam B HaddadCarrie L Byington
Oct 24, 2007·Emergency Medicine Clinics of North America·Paul Ishimine
Apr 20, 2007·Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie·L Bensouda-GrimaldiE Autret-Leca
Nov 9, 2006·Advances in Pediatrics·Olakunle B Akintemi, Kenneth B Roberts
Jun 1, 2005·Pediatric Clinics of North America·Amanda C CohnLarry K Pickering
Apr 17, 2014·Vaccine·Kalpana ManthiramAreej Hassan
Dec 3, 2014·Annals of Emergency Medicine·Samuel VaillancourtMichael J Schull
Mar 31, 2010·Acta Microbiologica Et Immunologica Hungarica·B Ivády

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.